CYRX Stock Analysis: Cryoport | NASDAQ

Cryogenic Freezers, Cryogenic Shippers, Biostorage, Temperature Monitoring

Total Rating 47

Safety 69

Buy Signal 0.17

Integrated Freight & Logistics
Industry Rotation: +4.4

Market Cap: 839M
Avg Turnover: 8.07M

Risk 3d forecast

Volatility61.3%

VaR 5^th Pctl9.16%

VaR vs Median-8.13%

Reward TTM

Sharpe Ratio1.31

Rel. Str. IBD92.7

Rel. Str. Peer Group82.6

Character TTM

Beta1.582

Beta Downside1.274

Hurst Exponent0.457

Drawdowns 3y

Max DD75.04%

CAGR/Max DD0.08

CAGR/Mean DD0.15

EPS (Earnings per Share)

Last SUE: 0.00
Qual. Beats: 0

Revenue

Rev. CAGR: -7.73%
Rev. Trend: -80.4%

Last SUE: 0.10
Qual. Beats: 0

Warnings

High Debt/EBITDA With Thin Interest Coverage

High Debt While Negative Cash Flow

Interest Coverage Ratio Critical

Altman Z'' In Financial Distress Zone

Below Avwap Earnings

Tailwinds

Rs Leader

Idiosyncratic Leader

Seasonality 11.6 years of data

Jan -1.6% 38

Feb -6.8% 22

Mar +1.4% 10

Apr -0.4% 10

May +13.1% 20

Jun +11.2% 57

Jul +1.9% 18

Aug +3.1% 15

Sep -2.7% 0

Oct -12.3% 29

Nov +1.7% 11

Dec +2.6% 14

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: CYRX Cryoport

Cryoport, Inc. (NASDAQ: CYRX), founded in 1999 and headquartered in Brentwood, Tennessee, provides temperature-controlled supply chain solutions across biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company operates through two segments: Life Sciences Services, which offers logistics, biostorage, bioservices, and cryopreservation, and Life Sciences Products, which manufactures and sells cryogenic freezers, dewars, and related accessories.

Its product portfolio includes the Cryoport Express Shippers, Cryoport Elite, the HV3 cryogenic shipping system, and the Smartpak Condition Monitoring System and Tec4Med IoT-based monitoring solutions. The company also offers IntegriCell services covering apheresis collection and cryopreservation, along with bioservices such as controlled temperature storage, kitting, labelling, fulfillment, sample management, and Qualified Person drug product release.

Cryoport operates within the cold chain logistics subsector of healthcare, a niche industry that is increasingly important due to the growth of cell and gene therapies, regenerative medicines, and advanced biologics, all of which require ultra-low temperature preservation (typically at or below -150°C using liquid nitrogen vapor) to maintain product viability throughout transportation and storage.

Headlines to Watch Out For

Cell and gene therapy approvals accelerate biopharma logistics shipment volume
Bioservices margin expansion from Cryogene and CLG acquisition integrations
Competition from specialty pharma couriers pressures pricing on enterprise contracts

Piotroski VR-10 (Strict) 2.0

Net Income: -36.3m TTM > 0 and > 6% of Revenue
FCF/TA: -0.03 > 0.02 and ΔFCF/TA 1.92 > 1.0
NWC/Revenue: 128.3% < 20% (prev 166.4%; Δ -38.11% < -1%)
CFO/TA 0.01 > 3% & CFO 7.97m > Net Income -36.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.08 > 1.5 & < 3
Outstanding Shares: last quarter (50.4m) vs 12m ago 0.37% < -2%
Gross Margin: 47.08% > 18% (prev 45.73%; Δ 1.35% > 0.5%)
Asset Turnover: 25.61% > 50% (prev 28.96%; Δ -3.35% > 0%)
Interest Coverage Ratio: -13.69 > 6 (EBIT TTM -28.9m / Interest Expense TTM 2.11m)

Altman Z'' 0.70

A: 0.32 (Total Current Assets 460.2m - Total Current Liabilities 221.0m) / Total Assets 756.2m
B: -0.94 (Retained Earnings -707.7m / Total Assets 756.2m)
C: -0.04 (EBIT TTM -28.9m / Avg Total Assets 728.0m)
D: 1.85 (Book Value of Equity 490.7m / Total Liabilities 265.5m)
Altman-Z'' = 0.70 = B

Beneish M -2.73

DSRI: 1.40 (Receivables 36.5m/28.4m, Revenue 186.5m/202.7m)
GMI: 0.97 (GM 45.73% / 47.08%)
AQI: 1.10 (AQ_t 0.27 / AQ_t-1 0.24)
SGI: 0.92 (Revenue 186.5m / 202.7m)
TATA: -0.06 (NI -36.3m - CFO 7.97m) / TA 756.2m)
Beneish M = -2.73 (Cap -4..+1) = A

What is the price of CYRX shares?

As of September 03, 2026, the stock is trading at USD 15.78 with a total of 413,254 shares traded. Over the past week, the price has changed by -4.77%, over one month by +1.87%, over three months by +0.25% and over the past year by +79.11%.

Current recommended Stop Loss: 13.90 (which is 11.9% or 2.8 ATR below the current price).

Is CYRX a buy, sell or hold?

Cryoport has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CYRX.

StrongBuy: 4
Buy: 2
Hold: 4
Sell: 0
StrongSell: 0

What are the forecasts/targets for the CYRX price?

Analysts Target Price	19.3	22.5%

Cryoport (CYRX) - Fundamental Data Overview as of 29 August 2026

Market Cap USD = 839.3m (839.3m USD * 1.0 USD.USD)
P/E Forward = 86.9565
P/S = 4.5012
P/B = 1.8884
P/EG = 62.1277
Revenue TTM = 186.5m USD
EBIT TTM = -28.9m USD
EBITDA TTM = -3.13m USD
Long Term Debt = 985k USD (from longTermDebt, last quarter)
Short Term Debt = 190.2m USD (from shortTermDebt, last quarter)
Debt = 277.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 45.2m
Net Debt = -119.5m USD (calculated: Debt 277.2m - CCE 396.7m)
Enterprise Value = 719.8m USD (839.3m + Debt 277.2m - CCE 396.7m)
Interest Coverage Ratio = -13.69 (Ebit TTM -28.9m / Interest Expense TTM 2.11m)
EV/FCF = -35.39x (Enterprise Value 719.8m / FCF TTM -20.3m)
FCF Yield = -2.83% (FCF TTM -20.3m / Enterprise Value 719.8m)
FCF Margin = -10.91% (FCF TTM -20.3m / Revenue TTM 186.5m)
Net Margin = -19.45% (Net Income TTM -36.3m / Revenue TTM 186.5m)
Gross Margin = 47.08% ((Revenue TTM 186.5m - Cost of Revenue TTM 98.7m) / Revenue TTM)
Gross Margin QoQ = 46.61% (prev 45.85%)
Tobins Q-Ratio = 0.95 (Enterprise Value 719.8m / Total Assets 756.2m)
Interest Expense / Debt = 0.76% (Interest Expense 2.11m / Debt 277.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -22.8m (EBIT -28.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.08 (Total Current Assets 460.2m / Total Current Liabilities 221.0m)
Debt / Equity = 0.56 (Debt 277.2m / totalStockholderEquity, last quarter 490.7m)
Debt / EBITDA = 38.19 (negative EBITDA) (Net Debt -119.5m / EBITDA -3.13m)
Debt / FCF = 5.88 (negative FCF - burning cash) (Net Debt -119.5m / FCF TTM -20.3m)
Total Stockholder Equity = 500.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.98% (Net Income -36.3m / Total Assets 756.2m)
RoE = -7.25% (Net Income TTM -36.3m / Total Stockholder Equity 500.4m)
RoCE = -5.76% (EBIT -28.9m / Capital Employed (Equity 500.4m + L.T.Debt 985k))
RoIC = -3.19% (negative operating profit) (NOPAT -22.8m / Invested Capital 716.1m)
WACC = 8.83% (E(839.3m)/V(1.12b) * Re(11.55%) + D(277.2m)/V(1.12b) * Rd(0.76%) * (1-Tc(0.21)))
Discount Rate = 11.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 84.06 | Cagr: 1.28%
[DCF] Fair Price = unknown (Cash Flow -20.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -80.37 | Revenue CAGR: -7.73% | SUE: 0.10 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.17 | Chg30d=-6.12% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.77 | Chg30d=-5.00% | Revisions=+0% | GrowthEPS=-13.5% | GrowthRev=+11.0%
EPS next Year (2027-12-31): EPS=-0.66 | Chg30d=-6.98% | Revisions=+25% | GrowthEPS=+13.9% | GrowthRev=+10.0%
[Analyst] Revisions Ratio: +0% (up=2, down=2)